Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Journal of Clinical Microbiology & Infectious Diseases
Published in: European Journal of Clinical Microbiology & Infectious Diseases 1/2018

01-01-2018 | Review

Similarities and differences between doxycycline and minocycline: clinical and antimicrobial stewardship considerations

Authors: B. A. Cunha, J. Baron, C. B. Cunha

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 1/2018

Login to get access

Abstract

Doxycycline and, to a lesser extent, minocycline, have been used for decades to treat various serious systemic infections, but many physicians remain unfamiliar with their spectrum, interpretation of susceptibility results, pharmacokinetic/pharmacodynamic (PK/PD) properties, optimal dosing regimens, and their activity against MRSA, VRE, and multidrug-resistant (MDR) Gram-negative bacilli, e.g., Acinetobacter sp. This article reviews the optimal use of doxycycline and minocycline to treat a variety of infections and when minocycline is preferred instead of doxycycline.
Appendix
Available only for authorised users
Literature
1.
Jonas M, Comer JB, Cunha BA (1984) Tetracyclines. In: Ristuccia AM, Cunha BA (eds) Antimicrobial therapy. Raven Press, New York, pp 219–234
2.
Cunha BA (1985) Clinical uses of the tetracyclines. In: Hlavka JJ, Boothe JH (eds) The tetracyclines. Handbook of experimental pharmacology (continuation of Handbuch der experimentellen Pharmakologie), vol 78. Springer, Berlin, Heidelberg, pp 393–404
3.
Eisen DP (2010) Tetracycline. In: Grayson ML, Crowe SM, McCarthy JS, Mills J, Mouton JW, Norrby SR, Paterson DL, Pfaller MA (eds) Kucer’s the use of antibiotics, 6th edn. Arnold, London, pp 843–850
4.
5.
6.
7.
Cunha BA (2006) New uses for older antibiotics: nitrofurantoin, amikacin, colistin, polymyxin B, doxycycline, and minocycline revisited. Med Clin North Am 90:1089–1107CrossRefPubMed
8.
Cunha CB, Cunha BA (eds) (2017) Antibiotic essentials, 15th edn. JayPee Medical Publishers, New Delhi
9.
10.
Cunha BA (2009) Doxycycline for nursing home acquired pneumonia (NHAP). Scand J Infect Dis 41:77–78CrossRefPubMed
11.
Dallas SD, McGee L, Limbago B, Patel JB, McElmeel ML, Fulcher LC et al (2013) Development of doxycycline MIC and disk diffusion interpretive breakpoints and revision of tetracycline breakpoints for Streptococcus pneumoniae. J Clin Microbiol 51:1798–1802CrossRefPubMedPubMedCentral
12.
Jones RN, Stilwell MG, Wilson ML, Mendes RE (2013) Contemporary tetracycline susceptibility testing: doxycycline MIC methods and interpretive criteria (CLSI and EUCAST) performance when testing Gram-positive pathogens. Diagn Microbiol Infect Dis 76:69–72CrossRefPubMed
13.
Cunha BA, Domenico P, Cunha CB (2000) Pharmacodynamics of doxycycline. Clin Microbiol Infect 6:270–273CrossRefPubMed
14.
Chopra I (1985) Mode of action of the tetracyclines and the nature of bacterial resistance to them. In: Hlavka JJ, Boothe JH (eds) The tetracyclines. Handbook of experimental pharmacology (continuation of Handbuch der experimentellen Pharmakologie), vol 78. Springer, Berlin, Heidelberg, pp 317–392
15.
Tilton RC (1984) Antimicrobial susceptibility testing. In: Ristuccia AM, Cunha BA (eds) Antimicrobial therapy. Raven Press, New York, pp 137–145
16.
Cunha BA (1997) Problems arising in antimicrobial therapy due to false susceptibility testing. J Chemother 9:25–35PubMed
17.
Cunha BA (2014) Minocycline is a reliable and effective oral option to treat meticillin-resistant Staphylococcus aureus skin and soft-tissue infections, including doxycycline treatment failures. Int J Antimicrob Agents 43:386–387CrossRefPubMed
18.
Cunha BA (2014) Pharmacoeconomic advantages of oral minocycline for the therapy of methicillin-resistant Staphylococcus aureus (MRSA) skin and soft tissue infections (SSTIs). Eur J Clin Microbiol Infect Dis 33:1869–1871CrossRefPubMed
19.
Cunha BA (2013) Minocycline, often forgotten but preferred to trimethoprim–sulfamethoxazole or doxycycline for the treatment of community-acquired meticillin-resistant Staphylococcus aureus skin and soft-tissue infections. Int J Antimicrob Agents 42:497–499CrossRefPubMed
20.
Cunha BA (2010) Minocycline versus doxycycline for meticillin-resistant Staphylococcus aureus (MRSA): in vitro susceptibility versus in vivo effectiveness. Int J Antimicrob Agents 35:517–518CrossRefPubMed
21.
Cunha BA (2000) Minocycline versus doxycycline in the treatment of Lyme neuroborreliosis. Clin Infect Dis 30:237–238CrossRefPubMed
22.
Stamey TA, Govan DE, Palmer JM (1965) The localization and treatment of urinary tract infections: the role of bactericidal urine levels as opposed to serum levels. Medicine (Baltimore) 44:1–36CrossRef
23.
Cunha BA, Comer JB (1979) Pharmacokinetic considerations in the treatment of urinary tract infections. Conn Med 43:347–353PubMed
24.
Cunha BA (2012) Oral doxycycline for non-systemic urinary tract infections (UTIs) due to P. aeruginosa and other Gram negative uropathogens. Eur J Clin Microbiol Infect Dis 31:2865–2868CrossRefPubMed
25.
Hamid NS, Cunha BA, Klein NC (2005) Falsely high antibiotic resistance in community-acquired E. coli UTIs requiring hospitalization. Mayo Clin Proc 80:824CrossRefPubMed
26.
27.
Pogue JM, Neelakanta A, Mynatt RP, Sharma S, Lephart P, Kaye KS (2014) Carbapenem-resistance in gram-negative bacilli and intravenous minocycline: an antimicrobial stewardship approach at the Detroit Medical Center. Clin Infect Dis 59:S388–S393CrossRefPubMed
28.
29.
Cunha CB (2017) Principles of antimicrobial stewardship. In: LaPlante KL, Cunha CB, Morrill HJ, Rice LB, Mylonakis E (eds) Antimicrobial stewardship: principles and practice. London, CABI Publishers, pp 1–7
30.
Hung YP, Lee JC, Lin HJ, Liu HC, Wu YH, Tsai PJ, Ko WC (2015) Doxycycline and tigecycline: two friendly drugs with a low association with Clostridium difficile infection. Antibiotics (Basel) 4:216–229CrossRef
31.
Smith K, Leyden JJ (2005) Safety of doxycycline and minocycline: a systematic review. Clin Ther 27:1329–1342CrossRefPubMed
32.
33.
Ritchie DJ, Garavaglia-Wilson A (2014) A review of intravenous minocycline for treatment of multidrug-resistant Acinetobacter infections. Clin Infect Dis 59:S374–S380CrossRefPubMed
34.
35.
Cunha CB, Cunha BA (2017) Antimicrobial therapy for Legionnaire’s disease: antibiotic stewardship implications. Infect Dis Clin North Am 31:179–191CrossRefPubMed
36.
Cunha BA (2006) Oral antibiotic therapy of serious systemic infections. Med Clin North Am 90:1197–1222CrossRefPubMed
37.
Cullmann W (1996) Comparative evaluation of orally active antibiotics against community-acquired pathogens: results of eight European countries. Chemotherapy 42:11–20CrossRefPubMed
38.
Shea KW, Cunha BA, Ueno Y, Abumustafa F, Qadri SMH (1995) Doxycycline activity against Streptococcus pneumoniae. Chest 108:1775–1776CrossRefPubMed
39.
Cunha BA, Gran A, Raza M (2015) Persistent extended-spectrum β-lactamase-positive Escherichia coli chronic prostatitis successfully treated with a combination of fosfomycin and doxycycline. Int J Antimicrob Agents 45:427–429CrossRefPubMed
40.
Semenitz E, Lackner M (1977) Comparison of the antibacterial efficacy of doxycycline and tetracycline. Med Klin 22:12–16
41.
Carris NW, Pardo J, Montero J, Shaeer KM (2015) Minocycline as a substitute for doxycycline in targeted scenarios: a systematic review. Open Forum Infect Dis 2:ofv178CrossRefPubMedPubMedCentral
42.
Veeraraghavan B, Shankar C, Vijayakumar S (2016) Can minocycline be a carbapenem sparing antibiotic? Current evidence. Indian J Med Microbiol 34:513–515CrossRefPubMed
43.
Lashinsky JN, Henig O, Pogue JM, Kaye KS (2017) Minocycline for the treatment of multidrug and extensively drug-resistant A. baumannii: a review. Infect Dis Ther 6:199–211CrossRefPubMedPubMedCentral
44.
Lawlor MT, Sullivan MC, Levitz RE, Quintiliani R, Nightingale C (1990) Treatment of prosthetic valve endocarditis due to methicillin-resistant Staphylococcus aureus with minocycline. J Infect Dis 161:812–814CrossRefPubMed
45.
Nicolau DP, Freeman CD, Nightingale CH, Coe CJ, Quintiliani R (1994) Minocycline versus vancomycin for treatment of experimental endocarditis caused by oxacillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 38:1515–1518CrossRefPubMedPubMedCentral
46.
Naoi T, Shimazaki H, Sawada M (2016) The rapid effectiveness of minocycline against scrub typhus meningoencephalitis. Intern Med 55:805–809CrossRefPubMed
47.
Sakamoto T, Kikuchi K, Mineura K, Kowada M, Nakagomi O (1990) MRSA meningitis in postoperative patients. Report of 4 cases. Jpn J Antibiot 43:1137–1142CrossRefPubMed
48.
Krol V, Kogan V, Cunha BA (2008) Q fever bioprosthetic aortic valve endocarditis (PVE) successfully treated with doxycycline monotherapy. Heart Lung 37:157–160CrossRefPubMed
49.
Greig SL, Scott LJ (2016) Intravenous minocycline: a review in Acinetobacter infections. Drugs 76:1467–1476CrossRefPubMed
50.
Turner RB, Smith CB, Martello JL, Slain D (2014) Role of doxycycline in Clostridium difficile infection acquisition. Ann Pharmacother 48:772–776CrossRefPubMed
51.
Doernberg SB, Winston LG, Deck DH, Chambers HF (2012) Does doxycycline protect against development of Clostridium difficile infection? Clin Infect Dis 55:615–620CrossRefPubMedPubMedCentral
52.
Thomas J, Walker C, Bradshaw M (2000) Long-term use of subantimicrobial dose doxycycline does not lead to changes in antimicrobial susceptibility. J Periodontol 71:1472–1483CrossRefPubMed
53.
Garrido-Mesa N, Zarzuelo A, Gálvez J (2013) What is behind the non-antibiotic properties of minocycline? Pharmacol Res 67:18–30CrossRefPubMed
54.
55.
Di Caprio R, Lembo S, Di Costanzo L, Balato A, Monfrecola G (2015) Anti-inflammatory properties of low and high doxycycline doses: an in vitro study. Mediators Inflamm 2015:329418CrossRefPubMedPubMedCentral
56.
Leite LM, Carvalho AG, Ferreira PL, Pessoa IX, Gonçalves DO, Lopes Ade A et al (2011) Anti-inflammatory properties of doxycycline and minocycline in experimental models: an in vivo and in vitro comparative study. Inflammopharmacology 19:99–110CrossRefPubMed
57.
Kholmukhamedov A, Czerny C, Hu J, Schwartz J, Zhong Z, Lemasters JJ (2014) Minocycline and doxycycline, but not tetracycline, mitigate liver and kidney injury after hemorrhagic shock/resuscitation. Shock 42:256–263CrossRefPubMedPubMedCentral
58.
Falagas ME, Vardakas KZ, Kapaskelis A, Triarides NA, Roussos NS (2015) Tetracyclines for multidrug-resistant Acinetobacter baumannii infections. Int J Antimicrob Agents 45:455–460CrossRefPubMed
59.
Colton B, McConeghy KW, Schreckenberger PC, Danziger LH (2016) I.V. minocycline revisited for infections caused by multidrug-resistant organisms. Am J Health Syst Pharm 73:279–285CrossRefPubMed
60.
Neonakis IK, Spandidos DA, Petinaki E (2014) Is minocycline a solution for multidrug-resistant Acinetobacter baumannii? Future Microbiol 9:299–305CrossRefPubMed
Metadata
Title
Similarities and differences between doxycycline and minocycline: clinical and antimicrobial stewardship considerations
Authors
B. A. Cunha
J. Baron
C. B. Cunha
Publication date
01-01-2018
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 1/2018
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-017-3081-x

Other articles of this Issue 1/2018

European Journal of Clinical Microbiology & Infectious Diseases 1/2018 Go to the issue

Review

Impact of nasopharyngeal microbiota on the development of respiratory tract diseases

Original Article

Extensive colonization with carbapenemase-producing microorganisms in Romanian burn patients: infectious consequences from the Colectiv fire disaster

Original Article

Prevalence and risk factors for intestinal carriage of CTX-M-type ESBLs in Enterobacteriaceae from a Thai community

Original Article

Clinical significance of Aspergillus species isolated from respiratory specimens in patients with Mycobacterium avium complex lung disease

Original Article

Automated direct screening for resistance of Gram-negative blood cultures using the BD Kiestra WorkCell

Original Article

Determination of avidity of IgG against protein antigens from Streptococcus pneumoniae: assay development and preliminary application in clinical settings
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits